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Although thiazolidinediones (TZDs) were found to be ligands for peroxisome proliferators-activated receptorγ (PPARγ), the
mechanism by which TZDs exert their anticancer eﬀect remains unclear. Furthermore, the eﬀe c to fT Z D so nm e t a s t a t i ca n d
angiogenesis potential of cancer cells is unknown. Our results in this paper show that rosiglitazone inhibited SGC-7901 gastric
cancer cells growth, caused G1 cell cycle arrest and induced apoptosis in a dose-dependent manner. The eﬀects of rosiglitazone
on SGC-7901 cancer cells were completely reversed by treatment with PPARγ antagonist GW9662. Rosiglitazone inhibited SGC-
7901 cell migration, invasiveness, and the expression of MMP-2 in dose-dependent manner via PPARγ-independent manner.
RosiglitazonereducedtheVEGFinducedangiogenesisofHUVECindose-dependentmannerthroughPPARγ-dependentpathway.
Moreover, rosiglitazone did not aﬀect the expression of VEGF by SGC-7901 cells. Our results demonstrated that by PPARγ ligand,
rosiglitazone inhibited growth and invasiveness of SGC-7901 gastric cancer cells and angiogenesis in vitro via PPARγ-dependent
or -independent pathway.
Copyright © 2008 Qing He et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Peroxisome proliferator-activated receptor gamma (PPARγ)
is a member of the ligand-inducible nuclear receptor
superfamily. After activation, PPARγ associates with the 9-
cis retinoic acid receptor (RXR) to form functional het-
erodimers, which binds to the PPAR response element of
the target genes and regulates the expression of these genes.
Previous documents have shown that the PPARγ/RXR signal
pathway plays critical role in a variety of biological processes,
including adipogenesis, glucose metabolism, inﬂammation
as well as inhibition of normal and tumor cells growth [1].
Thiazolidinediones (TZDs) are synthetic agonists for
PPARγ. These PPARγ ligands were clinically used as antidi-
abetic drugs which could attenuate the insulin resistance
associated with obesity, hypertension, and impaired glucose
tolerance in humans [2]. Recent studies have suggested that
PPARγ is a potential molecular target for anticancer drug
development, due to the increased expression of PPAR in
several cancer cells. It has been reported that TZDs could
inhibitgrowthandinduceapoptosisinavarietyofcancercell
lines. More importantly, TZDs exhibited antitumor activities
in vivo in the prevention of prostate, liver, and pituitary
cancers. Although increasing evidence showed that TZDs are
potential anticancer agents [3], the mechanisms underlying
the antitumor eﬀects are not well understood. TZDs were
initially thought to inhibit the cancer cells proliferation
through regulation of expression of PPARγ-mediated target
genes. However, recent evidence revealed that the antitumor
eﬀects of TZDs exist via PPARγ-independent mechanisms in
various types of cancers [4–6].
We previously found the expression of PPARγ decreased
in primary and metastatic gastric carcinoma, compared
with normal gastric tissues [7]. Recent studies in gastric
cancer cells demonstrated that TZDs treatment resulted in
signiﬁcant growth arrest both in cultured cell and in nude
mice models [8–12]; however, the eﬀects of PPARγ ligands
on invasiveness and angiogenesis of gastric cancer are still2 PPAR Research
unclear. Therefore, this work was undertaken to investigate
the eﬀects of PPARγ agonists, such as rosiglitazone, on cell
growth and the invasiveness in human cell line SGC-7901, as
well as on angiogenesis in vitro.
2. METHODS
2.1. Cellculture
Human gastric cancer cell line, SGC-7901, was obtained
from the Type Culture Collection of Chinese Academy
of Sciences (Shanghai, China). Human umbilical vein
endothelialcells(HUVECs)werepurchasedfromtheKeygen
Technology Company (Najing, China). SGC7901 cells and
HUVECs were cultured in RPMI-1640 medium (GIBCO,
Carlsbad, Calif, USA) containing 10% fetal bovine serum
(FBS) and 1% antibiotics (100U/mL penicillin G, 100μg/mL
streptomycin sulfate, Sigma-Aldrich, Mo, USA).
2.2. RT-PCR
Total RNA was isolated using TRIzol Reagent (Invitrogen,
Carlsbad, Calif, USA) according to the manufacturer’s
instructions. Reverse transcription reaction was performed
with random hexamer primers and a SuperScript Reverse
transcriptase kit (Invitrogen, Carlsbad, Calif, USA). The
sequences of speciﬁc primers were as follows: PPARγ mRNA,
forward, 5 -TCT CTC CGT AAT GGA AGA CC-3 ,a n d
reverse, 5 -GCA TTA TGA GAC ATC CCC AC-3 . MMP-
2 mRNA, forward, 5 -GGC CCT GTC ACT CCT GAG AT-
3 ,a n dr e v e r s e ,5  -GGC ATC CAG GTT ATC GGG GA-3 .
VEGF mRNA, forward, 5 -GAC AAg AAA ATC CCT GTG
GGC-3 ,a n dr e v e r s e5  -AAC GCG AGT CTG TGT TTT
TGC-3 . β- a c t i nm R N A ,f o r w a r d ,5  -CTT CTA CAA TGA
GCT GCG TA-3 ,a n dr e v e r s e ,5  -TCA TGA GGT AGT CAG
TCA GG-3 . PCR conditions were 94◦C, 30 seconds, 55–
57◦C (depending on the primer set), 30 seconds, and 72◦C, 1
minute with 35 cycles using Taq PCR MasterMix (Tianwei,
Beijing, China). The resultant PCR products were 474bp
(PPARγ), 243bp (β-actin), 474bp (MMP-2), and 169bp
(VEGF). PCR products were electrophoresed on a 1.2%
agarose gel and visualized by ethidium bromide staining.
2.3. Quantitativereal-timeRT-PCRanalysis
ThePCRreactionswereperformedinaBrilliantSYBRGreen
QPCR master mix (Stratagene, Calif, USA) according to
the manufacturer’s instructions. The sequences of speciﬁc
primers were the same as for RT-PCR. After 10 minutes at
95◦C to denature the cDNA, the cycling conditions were
95◦C, 1 minute, 55–57◦C (depending on the primer set), 30
seconds, and 72◦C, 1 minute with 40 cycles. The LightCycler
software constructed the calibration curve by plotting the
crossing point (Cp), and the numbers of copies in unknown
samples were calculated by comparison of their Cps with the
calibration curve. To correct diﬀerences in both RNA quality
and quantity between samples, the data were formalized to
those for β-actin.
2.4. Westernblotting
The cells proteins were extracted according to NE-PER
Nuclear and Cytoplasmic Extraction Reagents kit (Pierce,
Rockford, Ill, USA). Protein concentration of each sample
was assayed using BCA Protein Assay Reagent according
to manufacturer’s instructions (Pierce Biotechnology, Rock-
ford, Ill, USA). Twenty micrograms of proteins of diﬀerent
groups were separated in 10% SDS-PAGE, and transferred
onto PVDF membrane (Invitrogen, Carlsbad, Calif, USA).
Five percent of milk (blocking solution) was loaded over the
membrane and incubated for 1 hour at room temperature
with agitation. The membranes were then incubated with
the mouse antihuman PPARγ antibody at a dilution of
1:200 (Santa Cruz, Calif, USA), the mouse antihuman
MMP-2 antibody (1:400, Neomarker, Calif, USA), the rabbit
antihuman VEGF antibody (1:200, Zymed, Calif, USA),
and the mouse antihuman β-actin (1:200, Xiaxin, China)
overnight at 4◦C with agitation. After being washed with
0.1% Tween 20 in Tris-saline, three times, the membranes
were incubated with biotin-labeled antirabbit or mouse IgG
for 1 hour at room temperature with agitation. Reactive
protein was detected using ECL chemiluminescence system
(Pierce, Rockford, Ill, USA).
2.5. ELISAofsecretedVEGF
The eﬀect of RGZ on VEGF release in tumor cells was
measured by ELISA. Cells grown in 90mm plates were
exposed to various concentrations of RGZ (1–20μM) or
vehicle with or without GW9662 (2.5μM, pretreated 1
hour) for 24 hours. VEGF concentration in the supernatant
was measured using a VEGF ELISA kit (R & D systems,
Minneapolis, Minn, USA).
2.6. Cellviability
The viability of the cells was assessed by MTT assay.
Brieﬂy, cells grown in 96-wells were exposed to various
concentrations of RGZ with or without GW9662 (2.5μM,
pretreated 1 hour), for 24, 48, or 72 hours. Then, 20μL
of MTT (5mg/mL) was added to each well, and cells were
incubated continuously at 37◦Cf o r4h o u r s .A f t e rr e m o v a l
of medium, the crystals were dissolved in DMSO, and
absorbance was assessed at 570nm with a microplate reader.
2.7. Cellcycleandapoptosisanalysis
Cells treated with RGZ (1–20μM) or vehicle with or without
GW9662 (2.5μM ,p r e t r e a t e d1h o u r )f o r4 8h o u r sw e r e
collected and ﬁxed in cold 70% ethanol. Then, the samples
were treated with RNase, stained with 50mg/mL propidium
iodide (PI), and analysed by EPICS Elite ﬂow cytometer
(Coulter Electronics, Fla, USA).
2.8. Invasionassay
The ability of cells to invade through a Matrigel-coated
ﬁlter was measured in transwell chambers (Corning,
NY, USA). Polyvinylpyrrolidone-free polycarbonate ﬁltersQing He et al. 3
(pore size 8μm) were coated with basement membrane
Matrigel (50μL/ﬁlter) (BD, Bedford, Ohio, USA). The mem-
brane was washed in PBS to remove excess ligand, and the
lowerchamberwasﬁlledwith0.6mLofRPMI-1640medium
containing 10% fetal bovine serum (FBS). Cells were serum-
starved overnight (0.5% FBS), harvested with trypsin/EDTA,
and washed twice with serum-free RPMI-1640 medium.
Cells were resuspended in migration medium (RPMI-1640
medium with 0.5% FBS), and 0.1mL migration medium
containing 1 × 105 cells was added to the upper chamber.
After incubation with RGC (1–20μM) with or without
GW9662 (2.5μM, pretreated 1 hour) at 37◦C for 24 hours,
thecellsontheuppersurfaceofthemembranewereremoved
using a cotton swab. The migrant cells attached to the lower
surface were ﬁxed in 10% formalin at room temperature for
30 minutes and stained with hematoxylin. The numbers of
migrated cells were counted under a microscope.
2.9. Scratchwound-healingmotilityassays
Gastriccancercellswereseededon60mmplatesandallowed
to grow to conﬂuence. Conﬂuent monolayers were scratched
with a pipette tip and maintained under RGZ (1–20μM)
with or without GW9662 (2.5μM, pretreated 1 hour) for
24 hours. Plates were washed once with fresh medium to
remove nonadherent cells and then photographed. The cell
migrationwasevaluatedbycountingcellsthatmigratedfrom
the wound edge.
2.10. InvitroAngiogenesisassay
The angiogenesis assays were performed as per the manufac-
turer’s instructions, that is, transfer 50μLo fE C M a t r i x T M
solution to each well of a precooled 96-well tissue culture
plate on ice. Incubate at 37◦Cf o r1h o u rt oa l l o wt h e
matrix solution to solidify. Harvest human umbilical vein
endothelial cells (HUVECs) resuspend and Seed 5×103 cells
per well onto the surface of the polymerized ECMatrixTM.
Incubate with RGC (1–20μM) with or without GW9662
(2.5μM, pretreated 1 hour) at 37◦C for 12 hours. Inspect
tube formation under an inverted light microscope at 100 X
magniﬁcation.
2.11. Zymography
Cells were cultured for 24 hours in serum-free medium,
washed twice, and ﬁnally treated with RGZ (1–20μM)
with or without GW9662 (2.5μM, pretreated 1 hour)
for a further 48 hours. The supernatants were collected
and concentrated, using centrifugal ﬁlter devices (Milli-
pore Corp., Bedford, Mass, USA) and the protein content
was determined using BCA Protein Assay Reagent. Equal
amounts of protein (20μg) were mixed with SDS sample
buﬀer without reducing agents and incubated for 40 min-
utes at 37◦C. For gelatinolytic activity, the assay samples
were separated on polyacrylamide gels containing 1mg/mL
gelatin. After electrophoresis, the gels were stained for 1
hour in a 45% methanol/10% acetic acid mixture containing
coomassie brilliant blue G250 and destained. Zymograms
were photographed after 10 hours of incubation at 37◦C.
2.12. Statisticalanalysis
Data are expressed as mean ± standard deviation (SD)
of three independent experiments, each done in triplicate.
Diﬀerences between control and experiment groups were
analyzed using the t-test. P<. 05 was considered statistically
signiﬁcant.
3. RESULTS
3.1. RGZinhibitedproliferationand
inducedapoptosisinSGC-7901cellsthrough
PPARγ-dependentmechanism
In SGC-7901 cells, the expression of PPARγ was observed by
RT-PCR and western blot (not shown).
RGZ (0.1–100μM) treatment for 24, 48, and 72 hours
inhibited cells growth in a dose- and time-dependent
manners in SGC-7901 gastric cancer cell line as determined
by MTT assay. Pretreatment with the highly selective PPARγ
antagonist GW9662 (2.5μM) reversed the eﬀect of RGZ on
cell viability (see Figure 1(a)).
To explore whether the growth inhibition of RGZ in
SGC-7901 cells was caused by apoptosis, we analyzed the
sub-G1 population of the cells after treatment with RGZ
(1–20μM) for 48 hours. RGZ induced apoptosis in a dose-
dependent manner, which was also reversed completely by
2.5μM GW9662 treatment (see Figure 1(b)).
Furthermore, to determine whether the inhibitory eﬀect
ofRGZoncellviabilityisassociatedwiththearrestofthecell
cycle, we analyzed the cell cycle progression after treatment
with RGZ (1–20μM) for 48 hours. RGZ treatment increased
the number of cells in the G1-G0 and decreased the number
ofcellsintheSphasesindose-dependentmanner.Theeﬀects
of RGZ on cell cycle of SGC-7901 cells were also reversed by
2.5μM GW9662 (see Figure 1(c)).
3.2. RGZinhibitedSGC-7901cellsmigration
andinvasivenessthroughPPARγ-independent
mechanism
After treatment with RGZ (1–20μM) for 48 hours, the
number of cells migrated to the scratched area was 60 ±
3.1cells/mm2,5 8± 2.7cells/mm2,4 9± 2.8cells/mm2,2 7±
2.9cells/mm2,a n d2 0± 1.9cells/mm2,r e s p e c t i v e l y ,w h i c h
were signiﬁcantly lower than those in control group (84 ±
3.4cells/mm2).GW9662treatmenthadnoeﬀectsonthecells
migration with inhibition induced by RGZ. The number of
the cells migrated to the scratched area treated with GW9662
and RGZ (1–20μM) for 48 hours was 61 ± 1.8cells/mm2,5 3
± 3cells/mm2,4 7± 2.5cells/mm2,2 9± 2.8cells/mm2,1 8
± 3.2cells/mm2, respectively, which were not diﬀerent from
those in the groups treated with RGZ alone (see Figure 2(a)).
The eﬀect of RGZ on the cells invasion through recon-
stituted basement membranes was analyzed using Matrigel-
coated invasion chambers. After treatment with RGZ (1–
20μM) for 48 hours, the cells attached to the lower surface of4 PPAR Research
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Figure 1: (a) RGZ (0.1–100μM) treatment for 24, 48, and 72 hours inhibited cell growth in a dose- and time-dependent manners in SGC-
7901 gastric cancer cell line, as determined by MTT assay, which was reversed completely by 2.5μM GW9662 pretreatment for 1 hour. Cell
viability was expressed as the percentage of cells under control conditions (0μM of RGZ or GW9662). (b) RGZ induced apoptosis in a
dose-dependent manner, which was also reversed completely by 2.5μM GW9662 pretreatment for 1 hour. (c) RGZ treatment increased the
number of cells in the G1-G0 and decreased the number of cells in the S phases in dose-dependent manner, which was reversed completely
by 2.5μM GW9662 pretreatment for 1 hour. Values are the means ± SD of three representative experiments. ∗Statistical signiﬁcance (P<. 05
or higher degree of signiﬁcance) versus vehicle-treated controls.
the ﬁlters were 256 ± 9cells/mm2, 248 ± 7cells/mm2, 219 ±
12cells/mm2, 174 ± 11cells/mm2, and 154 ± 10cells/mm2,
respectively, which were signiﬁcantly lower than those in
control group (279 ± 9cells/mm2). After cotreatment of the
cells with GW9662 and RGZ, the cells attached to the lower
s u r f a c ew e r e2 5 1± 29cells/mm2, 238 ± 12cells/mm2, 220 ±
7cells/mm2, 166 ± 16cells/mm2, and 148 ± 12cells/mm2,
respectively, which were not diﬀerent from those in the
groups treated with RGZ alone (see Figure 2(b)).
Metalloproteases (MMPs) have been demonstrated to
play a signiﬁcant role in tumor cell invasion [13]. In this
study, our results showed that RGZ inhibited the mRNA
and protein expression levels of MMP-2 in a dose-dependent
manner (see Figures 3(a), 3(c),a n dT a b l e s1, 2). Moreover,
the gel zymography results demonstrated that the activity
of MMP-2 decreased after RGZ (1–20μM) treatment for
48 hours in dose-dependent manner (see Figure 4(a)). The
inhibitory eﬀects of RGZ on MMP-2 were not aﬀected by
GW9662 treatment (see Figures 3(b), 3(c),a n d4(b)).
3.3. EffectsofRGZonangiogenesisinvitro
Matrigel-plated HUVECs elongated and migrated in the
presence of VEGF and formed tubular networks. RGZ
markedly suppressed the formation of the tube-like struc-
tures of HUVEC cells in a dose-dependent mannerQing He et al. 5
(see Figure 5(a)), which was completely antagonized by
GW9662 (see Figure 5(b)). These results suggested that
rosiglitazone exhibits antiangiogenic activity via PPARγ-
dependent mechanism.
TofurtherdeterminewhethertheeﬀectofRGZonangio-
genesis is due to the down regulation of the tumor-secreted
growth factors, we measured the expression levels of VEGF
in SGC-7901 cell cultured medium, after treatment with
various concentrations of RGZ. Our results demonstrated
thatRGZ(1–20μM)didnotchangetheexpressionofmRNA
and protein of VEGF in SGC-7901 cells (see Figures 3(a),
3(c),a n dTable 1), but also the results were conﬁrmed by
ELISA (see Figure 6).
4. DISCUSSION
As a potential molecular target for anticancer drug develop-
ment, PPARγ and its ligands have been extensively studied
in the past several years. Previous studies have shown that
PPARγ i se x p r e s s e di ns e v e r a lh u m a ng a s t r i c - c a n c e rc e l l
lines,includingMKN-7,MKN-28,MKN-45,andAGS.TZDs
could inhibit these cancer cell lines growths in vitro and in
vivo [9, 12]. Also, the growth inhibitory eﬀects of TZDs on
MKN45 cells depend on the PPARγ expression levels. The
growthinhibitionofTDZswasmoresigniﬁcantinthehigher
PPARγ expressing cells. Moreover, Lu et al. [10] found that
PPARγ (+/−) mice were more susceptible to MNU-induced
gastric cancer than wild-type (+/+) mice, and troglitazone
signiﬁcantly reduced the incidence of gastric cancer in
PPARγ (+/+) mice but not in PPARγ (+/−) mice. All these
resultsindicatedthatTZDsinhibitthecancercellsgrowthvia
PPARγ-dependent mechanism. Our results demonstrated
that RGZ, the most potent and selective synthetic ligand
of PPARγ, inhibited SGC-7901 gastric cancer cells growth,
caused G1 cell cycle arrest, and induced apoptosis in a
dose-dependent manner. The eﬀects of RGZ on SGC-7901
cancer cells were completely reversed by treatment with
PPARγ antagonist GW9662. These results indicated that
RGZ suppressed the SGC-7901 cancer cells growth in a
PPARγ-dependent mechanism.
In this study, we found that the RGZ inhibited inva-
sion, migration, and the secretion of MMP-2 of SGC-
7901 cells. The inhibitory eﬀects of RGZ on metastases
and MMP-2 activity were not directly mediated by PPARγ
activation, since these eﬀects were not reversed by GW9662
treatment. Our results were consistent with the previous
works on human adrenocortical cancer cell line H295R [14],
pancreatic cancer cells [15], and human myeloid leukemia
cells [16], which showed that PPARγ ligands act indepen-
dently of PPARγ activation in the invasion suppression and
down-regulation of MMP-2 activity. Recent papers showed
that PPARγ regulated E-cadherin expression and inhibited
growth and invasion of prostate cancer [17], and PPARγ
ligand troglitazone inhibited transforming growth factor-
beta-mediated glioma cell migration and brain invasion
[18]. But some studies have contrasting results that the
PPARγ,ciglitazone,inducedcellinvasion,throughactivation
of Pro-MMP-2, activation via the generation of ROS, and
the activation of ERK [19], and that PPARγ antagonists
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Figure 2: (a) Eﬀect of RGZ on the migration and (b) invasion of
SGC-7901 gastric cancer cells, which was reversed completely by
2.5μM GW9662 pretreatment for 1 hour. Values are the means
± SD of three representative experiments. ∗Statistical signiﬁcance
(P<. 05 or higher degree of signiﬁcance) versus vehicle-treated
controls.
induced vimentin cleavage and inhibited invasion in high-
grade hepatocellular carcinoma [20]. Further studies are
needed on the mechanism of PPARγ in cancer and invasion.
Recent investigations suggested that PPARγ ligands had
inhibitory eﬀects on tumor cell lines, but the eﬀects appear
not to be entirely elicited by the direct action on tumor cells.
Inhibition oftheneovascularizationmaybeanothertargetof
TZDs to suppress the growth of cancers. PPARγ is expressed
in endothelial cells, and the PPARγ ligands can inhibit the
proliferation of these cells induced by growth factors, or
cause their apoptosis in vitro [21–23]. It has been reported
that PPARγ ligands could inhibit choroidal, retinal, and
corneal neovascularization when administered intraocularly
[24–26]. In addition, systemic administration of rosiglita-
zone and troglitazone inhibits FGF2-induced angiogenesis;
thereby inhibiting primary tumor growth and metastasis
[27]. We observed that RGZ inhibited the angiogenesis of6 PPAR Research
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Figure 3: (a) RGZ (1–20 μ M) inhibited the mRNA and (c) protein expression levels of MMP-2 in a dose-dependent manner, which were
not aﬀected by 2.5μM GW9662 pretreatment for 1 hour (b), (c). RGZ (1–20 μ M) did not change the expression of VEGF in SGC-7901 cells
(a), (c).
Table 1: Expression of MMP-2 and VEGF after RZD treatment in SGC-7901 gastric cancers by real-time PCR.
Rosiglitazone (μmol/L) PPARγ MMP-2 VEGF
00 .132127 ±0.045513 0.008912 ±0.000133 0.61132 ±0.078921
10 .121878 ±0.034219 0.006003 ±0.000331∗ 0.620255 ±0.054671
30 .130134 ±0.0521137 0.005486 ±0.000541∗ 0.60728 ±0.036799
50 .137778 ±0.046222 0.005048 ±0.000346∗ 0.599438 ±0.076541
10 0.141171 ±0.038741 0.001924 ±0.000189∗ 0.624165 ±0.038966
20 0.143889 ±0.061237 0.001298 ±0.000267∗ 0.604246 ±0.065679
∗Statistical signiﬁcance (P<. 05 or higher degree of signiﬁcance) versus vehicle-treated controls.
Table 2: Expression of MMP-2 and VEGF after RZD and GW9662 cotreatment in SGC-7901 by real-time PCR.
Rosiglitazone (μmol/L) PPARγ MMP-2
00 .14161 ±0.055389 0.00975 ±0.000533
10 .137738 ± 0.030102 0.008974 ±0.000113∗
30 .134614 ± 0.029881 0.006003 ±0.000401∗
50 .141156 ± 0.564569 0.00564 ± 0.000246∗
10 0.135666 ± 0.034887 0.002182 ±0.000364∗
20 0.129278 ± 0.019262 0.001712 ±0.000178∗
∗Statistical signiﬁcance (P<. 05 or higher degree of signiﬁcance) versus vehicle-treated controls.Qing He et al. 7
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Figure 4: (a)The activity of MMP-2 was decreased after RGZ (1–20μM) treatment for 48 hours in dose-dependent manner. (b) The
inhibitory eﬀects of RGZ on MMP-2 were not aﬀected by 2.5μM GW9662 pretreatment for 1 hour.
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Figure 5: (a) RGZ markedly suppressed the formation of the tube-like structures of HUVEC cells in a dose-dependent manner, (b) which
was completely antagonized by 2.5μM GW9662 pretreatment for 1 hour.
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Figure 6: RGZ had no eﬀect on the secretion of VEGF of SGC-7901
cell.
HUVECs in dose-dependent manner via PPARγ pathway.
The eﬀects RGZ on the endothelium suggest that RGZ may
regulate tumor growth by targeting non-cell-autonomous
mechanisms.
Previous studies [5] showed that suppression of angio-
genesiscouldresultfromadecreaseinthelocallevelsofstim-
ulators (e.g., VEGF and FGF2) and/or an increase of endoge-
nous inhibitors of angiogenesis (e.g., thrombospondin)
produced by tumor cells. PPARγ ligands suppressed VEGF
production in colon carcinoma [28], human breast cancer
[29], and human renal cell carcinoma cells [30]. However,
contradictory results have also been reported in bladder and
prostatecancercellsinwhichPPARγ ligandsincreasedVEGF
production [31, 32]. Inconsistent with the above documents,
our results showed that RGZ did not change the secretion of
VEGF from SGC-7901.
Taken together, our results demonstrated that RGZ
inhibited growth and invasiveness of SGC-7901 gastric can-
cer cells and angiogenesis in vitro via PPARγ-dependent or
-independent pathway. Further study is needed to elucidate
the mechanisms by which RGZ exhibits diﬀerent manner.
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